Only a few studies include research of microvibration therapy in animal models. We examined effects of chronic vibroacustic-microvibration treatment on haemodynamics and antioxidative defense in experimental hypertension.Design and method:
Study was performed on spontaneously hypertensive (SHR) and normotensive (Wistar) rats. Animals were treated by VITAFON-T vibroacustic device 10 minutes/day. Mean arterial pressure (MAP), cardiac output (CO), renal blood flow (RBF), glomerular filtration and activity of anti-oxidative enzymes were determined after three weeks treatment.Results:
Vibroacustic treatment had no influence on MAP and CO, while RBF was increased in both Wistar and SHR vs. their respective controls (Wistar 21.45 ± 1.24 vs. 16.64 ± 2.59, p < 0.05; SHR 21.44 ± 2.41 vs.16.22 ± 2.05, p < 0.05 ml/min/kg). Additionally, treatment enhanced diuresis (81.84 ± 11.01 vs. 41.91 ± 3.23, p < 0.01 ml/24 h/kg) and stimulated glomerular filtration (12.16 ± 1.94 vs. 6.36 ± 0.75, p < 0.01 ml/min/kg) only in hypertensive rats. Glutathione peroxidase activity was elevated in both treated rat strains vs. respective controls (Wistar 73.14 ± 9.64 vs. 18.75 ± 3.01, p < 0.001; SHR 287.15 ± 26.3 vs. 205.09 ± 26.18, p < 0.05 U/gHb). Activity of superoxide dismutase was unchanged.Conclusions:
We conclude that vibroacustic microvibrations can’t ameliorate hypertension but are able to improve both renal blood supply and glomerular filtration, stimulate diuresis, and also enhance glutathione dependent antioxidative defense. This pioneering treatment expresses more beneficial effects in hypertensive animals.